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Abstract
Introduction: The causative role of new hydroxyethyl starch (HES 130/0.4) in renal dysfunction frequency (a > 50%
increase in serum creatinine or need for renal replacement therapy (RRT)) remains debated. Using the database of
a multicenter study focusing on patients with severe sepsis and septic shock, the present study aimed at
identifying factors associated with the occurrence of renal dysfunction.
Methods: Among the 435 patients in a multicenter study of patients with severe sepsis and septic shock in 15
Southern French ICUs, 388 patients surviving after 24 hour, without a history of renal failure were included. Factors
associated with renal dysfunction and RRT were isolated using a multivariate analysis with logistic regression.
Results: Renal dysfunction was reported in 117 (33%) patients. Ninety patients required RRT. Among study
participants, 379 (98%) were administered fluids in the first 24 hours of management: HES 130/0.4 only (n = 39),
crystalloids only (n = 63), or both HES 130/0.4 and crystalloids (n = 276). RRT was independently associated with
the need for vasopressors and the baseline value of serum creatinine in the first 24 hours. Multivariate analysis
indicated that male gender, SAPS II score, being a surgical patient, lack of decrease in SOFA score during the first
24 hours, and the interventional period of the study were independently associated with renal dysfunction.
Mortality increased in the presence of renal dysfunction (48% versus 24%, P < 0.01).
Conclusions: Despite being used in more than 80% of patients with severe sepsis and/or septic shock, the
administration of HES 130/0.4 in the first 24 hours of management was not associated with the occurrence of renal
dysfunction.
Introduction
In patients with severe sepsis and septic shock, acute
renal failure (ARF) is an independent factor for mortal-
ity [1,2]. In the last decade, significant efforts were made
to standardize the treatment of septic shock [3,4]. One
of the most important recommendations is volume
expansion that could also prevent ARF [5,6]. However,
the type of fluid, especially the use of colloids, for
volume expansion in septic shock remains a matter of
debate [7-11]. Indeed, despite a larger plasma volume
expansion power [12-14], the use of hydroxyethylstarch
(HES) is not related to better outcomes when compared
to isotonic crystalloids. In addition, use of HES has been
associated with the development of an impaired renal
function [7,8,15]. Thus, some experts suggest avoiding
the use of HES in septic shock [7-9].
Because recent HES have a lower molecular weight
(HES 130/0.4), some authors advocate their use in septic
patients [16,17]. In fact, controversial results have been
reported in the literature [18,19]. In the field of renal
transplant, two studies suggested a better renal tolerance
with low molecular weight HES, than with high molecu-
lar weight HES or gelatins [20,21]. In patients with sep-
tic shock, a recent study suggested that even the use of
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low molecular weight HES was associated with renal
dysfunction. In this study, HES 130/0.4 was used in the
first phase of the study when the initial optimization of
cardiac preload could be suspected as suboptimal when
compared with the final phase using crystalloids [22].
In 2006, a regional program of quality improvement in
patients with severe sepsis and septic shock was per-
formed in 15 Southern French ICUs in the Languedoc
Roussillon region. After an observational period (six
months), an educational program was implemented to
optimize the management of patients with severe sepsis
and/or septic shock (Sepsi d’Oc study) [23]. As in other
studies, the implementation of ten recommendations
based on the Surviving Sepsis Campaign [3] and French
recommendations were associated with an absolute
reduction (13%) of 28-day mortality rates [23].
During this study, information on the type and the
volume of fluid was collected in the first 24 hours of
patient management. We hypothesized that, in severe sep-
sis or septic shock patients, the use of HES 130/0.4 may be
associated with the development of renal dysfunction. The
study was aimed at finding the variables in the first 24
hours that were associated with the occurrence of renal
dysfunction in our cohort of patient. The secondary aims
were to determine the volume of each type of fluid used in
these patients, the relationship between the need for renal
replacement therapy (RRT) and the type of fluid, and the
outcome and the type of fluid.
Materials and methods
The present study was a part of Sepsi d’Oc (grants from
the University Hospital of Nîmes), a quality improvement
program for the management of severe sepsis in 15 ICUs
in southern France (Languedoc Roussillon, population:
2,402,000 habitants) [23]. Therefore, the Institutional
Review Board at the Nîmes University Hospital approved
this study and stated that informed consent was waived.
The patients or next of kin were informed of the study
and could decline participation in the study.
The design of the Sepsi d’Oc study
The design of the Sepsis d’Oc study has been described
elsewhere [23]. Briefly, the Sepsi d’Oc study compared
patients with severe sepsis and/or septic shock who
were seen during two periods. During the first six
months of 2006 (1 January to 30 June), an observational
study was performed while an intervention was pro-
posed in the second half of the year (1 July to 31
December). The intervention was based on the Surviving
Sepsis Campaign (Table 1) [3].
Patients
All patients with severe sepsis and septic shock accord-
ing to international criteria [3], were eligible for the
study. Exclusion criteria were moribund patients, immu-
nosuppression, and evolving severe sepsis or septic
shock sepsis for more than 24 hours.
Measurements
Age, sex, body mass index (BMI), simplified acute physiol-
ogy II (SAPS II) [24] and sequential organ dysfunction
(SOFA) [25] scores, the type (crystalloids or colloids or
both) and volume of fluid administered during the first 24
hours of severe sepsis and septic shock were studied. The
type of colloids was also collected. The type of fluids used
for volume expansion during the first six hours and during
the remaining 18 hours was also collected. Patient out-
comes were used to determine the 28-day mortality rate
and the occurrence of organ failure until day 28 (defined
by organ dysfunction and/or infection (ODIN) score [26]).
The present study (Figure 1)
From the Sepsi d’Oc study data base (institutional free
access with anonymized data), we analysed the factors
associated with the occurrence of renal dysfunction
defined by at least a 50% increase in plasma creatinine
concentrations (corresponding to acute kidney injury
network (AKIN) stage 1) [27] and/or the need of RRT.
Inclusion criteria
Patients included in the Sepsi d’Oc study, without end
stage renal disease, who were alive after the first 24
hours of severe and/or septic shock, participated in the
present analysis.
Exclusion criteria
Patients with end stage renal disease and those who died
during the first 24 hours of severe and/or septic shock
were excluded.
Measured parameters
In addition to variables measured in the Sepsi d’Oc
study, the occurrence of renal dysfunction as previously
Table 1 The bundle of 10 recommendations
Recommendations
# 1 Initial bacteriological samples drawn from sites that are suspected as
the source of infection blood cultures in the first three hours
# 2 Initiating an empirical antibiotics therapy in the first three hours
# 3 Measurement of arterial lactate within the first six hours
# 4 Volume expansion ≥20 ml/kg within the first six hours
# 5 A targeted MAP > 65 mmHg within the first six hours
# 6 Assessments of CVP and ScvO2 within the first six hours
# 7 Glucose control ≤8.3 mmol/l within the first 24 hours
# 8 Low doses of corticosteroids when norepinephrine requirement
at fewer than six hours
# 9 Using low tidal volume (≤8ml/kg of ideal body weight)
# 10 Adequate use of rhAPC within the first 24 hours
CVP: central venous pressure; MAP: mean arterial pressure; rhAPC:
recombinant human activated protein C; ScvO2: oxygen saturation of central
venous haemoglobin
Muller et al. Critical Care 2012, 16:R34
http://ccforum.com/content/16/1/R34
Page 2 of 8
defined was recorded. Information was collected on fluid
volumes and the need for vasoactive drugs (vasopressors
or inotropes) during the first 24 hours. Moreover, the
duration of different organ dysfunctions (ODIN score)
until day 28 was also recorded.
Statistical analysis
Quantitative variables are expressed as means (standard
deviation (SD)) or medians (first quartile (Q1), third
quartile (Q3)) according to variable distributions. The
qualitative variables are expressed as frequencies
(percentage).
A univariate analysis was first performed using chi-
square tests or Fisher exact tests for qualitative factors
and using analysis of variance or Mann-Whitney tests
for quantitative factors.
For model building, we applied backward introduction
of selected variables from univariate analysis (P-entry =
0.20). Data fitting was assessed by the Hosmer Leme-
show test. All analyses were performed using SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC) using a 2-sided
type 1 error rate of 0.05 as the threshold for statistical
significance.
Results
Patient population during the study period
In 2006, 6,902 patients were admitted to the 15 ICUs.
Five hundred and thirty-eight patients were initially
screened for eligibility. Two patients under 18 years of
age, 24 patients lacking
one criterion for severe sepsis (infection or Systemic
Inflammatory Response Syndrome or organ failure) and
Sepsi d’Oc study 
445 patients 
Observational period: 230 patients 
Interventional period: 215 patients 
57 excluded patients (Prior renal failure, 
death in the first 24 hours 
The present study 
388 patients analyzed for factors associated with RRT 
354 patients analyzed for factors associated with renal dysfunction 
34 (8.8%) excluded patients: 
patients with no RRT and 
without data concerning the 
course of serum creatinine in 
the first in the first 24 hours 
117 patients with 
renal dysfunction 
90 patients 
with RRT 
> 50% increase 
in serum 
creatinine 
27 patients 
≤ 50% increase in 
serum creatinine 
237 patients 
298 patients 
without RRT 
237 patients with no 
renal dysfunction 
Figure 1 Flow chart of the study. RRT, renal replacement therapy.
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67 patients presenting a non-inclusion criterion were
not included. Therefore, the Sepsi d’Oc study involved
445 patients.
Hemodynamic management
Among the 445 patients included in the Sepsi d’Oc
study, 41 patients had prior end-stage renal disease. Six-
teen patients died within the first 24 hours of manage-
ment. Therefore, 388 patients were included in the
present study (202 in the initial observational period,
186 in the second interventional period) (Figure 1). The
patient characteristics are shown in Table 2. During the
first 24 hours of severe sepsis or septic shock, 379 (98%)
out of 388 patients received a fluid administration con-
sisting of exclusively HES 130/0.4 (n = 39 (10%)) or
crystalloids (n = 63 (17%)), or both HES 130/0.4 and
crystalloids (n = 276 (73%)) (Figure 2). The mean total
amount of fluid given during the first 24 hours was
3,780 ± 2,487 ml (Table 3). During the first 24 hours,
red blood cell transfusion was required in 90 (24%)
patients and vasopressors and inotropes were given to
307 (79%) and 71 (18%) patients, respectively. The 28-
day mortality rate was 32%.
Patients with RRT and renal dysfunction
RRT was required in 90 (23%) out of 388 patients. In
the patients who did not undergo RRT, an increase in
plasma creatinine of at least 50% was found in 27 (7%)
patients. An increase in plasma creatinine of less than
50% was identified in 237 (61%) patients. Of note, the
course of the plasma creatinine during the first 24 hours
could not be determined in 34 (8.8%) patients (missing
data). A renal dysfunction was then confirmed in 117 of
364 patients (32%).
Factors associated with renal dysfunction
After univariate and multivariate analyses, male gender,
an increase in SAPS II scores, surgical patients, no
decrease in SOFA scores during the first 24 hours and
the interventional period of the study were indepen-
dently associated with renal dysfunction (Table 4). The
mortality rate was higher in patients with renal dysfunc-
tion than in those without renal dysfunction (48% versus
24%, P < 0.01).
Factors associated with RRT
After multivariate analysis, the need for vasopressors
and the baseline value of plasma creatinine were inde-
pendently associated with the need for RRT (Table 4).
The mortality rates were 52% in patients requiring RRT
and 26% in those not requiring RRT (P < 0.01).
Table 2 Patient characteristics (data are shown as the
median value with interquartile or in absolute value with
percentage)
Gender (Male/Female) 257/131 (66/34)
Age (years) (median [interquartile]) 66 [54 to 77]
SAPS II at admission (median [interquartile]) 44 [37 to 56]
SOFA at admission (median [interquartile]) 7 [5 to 9]
ODIN score at admission (median [interquartile]) 3 [3 to 4]
Type of admission
Medical (n, %) 257 66
Elective surgery (n, %) 16 4
Emergency surgery (n, %) 115 30
Site of causative infection
Pulmonary (n, %) 191 49
Peritonitis (n, %) 76 20
Biliary tract infection (n, %) 13 3
Urinary tract infection (n, %) 39 10
Blood (n, %) 39 10
Central nervous system (n, %) 17 14
Others (n, %) 48 12
Organ failure (with the duration of organ failure)
Cardiovascular (n, %) 332 86
Duration (median [interquartile]) 4 [2-9]
Respiratory (n, %) 336 87
Duration (median [interquartile]) 11 [5-21]
Neurologic (n, %) 97 25
Duration (median [interquartile]) 6 [3-13]
SAPS II, simplified acute physiology score II; SOFA, sequential organ
dysfunction score.
h h h 
Figure 2 Number of patients receiving each type of fluid
regimen during the initial 24-hour management period. HES,
hydroxyethyl starch.
Table 3 Volume of fluid administered during the periods
0 to 6 hours and 6 to 24 hours and the total of fluid
infused in the first 24 hours.
0 to 6 hours 6 to 24 hours Total
HES 938 ± 529 830 ± 731 1,344 ± 951
Crystalloids 1,575 ± 1,355 1,889 ± 1,427 2,965 ± 2,100
Total 2,098 ± 1,597 2,124 ± 1,596 3,780 ± 2,487
The volume of fluid is expressed in milliliters (mean ± standard deviation).
HES, hydroxyethyl starch.
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Table 4 Univariate and multivariate analyses for renal dysfunction and renal replacement therapy
Renal dysfunction Univariate
analysis
Multivariate
analysis
RRT Univariate
analysis
Multivariate
analysis
No (n =
237)
Yes (n =
117)
P Renal
dysfunction
OR - IC 95%
No RRT
N = 298
RRT
N = 90
P RRT
Age (mean ± SD)(year) 63 ± 16 67 ± 14 0.03 63 ± 16 68 ± 15 0.03
Female (n, %) 86 (36) 29 (25) 1 108 (36) 23 (25)
Male (n, %) 151 (64) 88 (75) 0.03 2 [1.15 to 3.49] 190 (64) 67 (75) 0.04
SAPS II at admission (median with
interquartile)
42
[35-52]
49
[40-61]
< 0.01 1.03 [1.01 to
1.05] per unit
43 [35 to
53]
50 [40 to
63]
< 0.01
Type of admission 1
Medical 171 (72) 67 (57) 3.49 [1.01-12.07] 200 (67) 57 (63)
Elective surgery 6 (3) 7 (6) 1.94 [1.13-3.35] 13 (4) 3 (3)
Emergency surgery 60 (25) 43 (37) 0.01 85 (29) 30 (33) 0.68
Fluid type (n, %)
None 5 (2) 2 (1) 0.24 7 (2) 2 (2) 0.89
Crystalloids 46 (19) 14 (12) 49 (17) 14 (16)
Colloids 19 (8) 14 (12) 28 (9) 11 (12)
both 166 (70) 87 (74) 214 (72) 63 (70)
Use of colloids (n, %) 185 (78) 101 (86) 0.07 241 (81) 74 (82) 0.82
Transfusion (n, %)
YES 47(20) 32 (28) 0.07 70 (23) 25 (26) 0.49
NO 190 (80) 82 (72) 228 (77) 65 (72)
Vasopressors (n, %)
YES 175 (74) 106 (91) < 0.01 225 (76) 82 (91) < 0.01 1
NO 62 (26) 11 (9) 73 (25) 8 (9) 2.61 [1.18 to
5.77]
Inotropic drug (n, %)
YES 39 (16) 30 (26) 0.04 49 (16) 22 (24) 0.09
NO 198 (84) 87 (74) 249 (84) 68 (76)
Decrease in SOFA between H0 and
H24 (n, %)
YES 88 (37) 27 (23) 1 191 (64) 66 (73)
NO 149 (63) 90 (77) < 0.01 2.49 [1.40-4.41] 107 (36) 24 (27) 0.11
Baseline mean arterial pressure (mean ±
SD) (mm Hg)
69 ± 22 69 ± 20 0.52 69 ± 22 69 ± 21 0.57
Baseline central venous pressure (mean
± SD) (mm Hg)(MD = 264)
12 ± 5 12 ± 5 0.78 12 ± 5 12 ± 5 0.99
Baseline arterial lactate (mean ± SD)
(mMol/l)(MD = 162)
3.4 ± 2.7 3.6 ± 2.8 0.68 3.4 ± 2.7 3.6 ± 3.0 0.99
History of renal dysfunction (n, %)
YES 11 (5) 3 (3) 0.40 12 (4) 3 (3) 1.00
NO 226 (95) 114 (97) 86 (96) 87 (97)
Baseline creatinine (mean ± SD)
(mMol/l)
122 ± 71 148 ± 84 < 0.01 119 ± 69 159 ± 87 < 0.01 1.006 [1.003-
1.009] per unit
Baseline renal SOFA (n, %) < 0.01 < 0.01
0 to 1 174 (73) 69 (59) 218 (73) 51 (57)
2-3 to 4 63 (27) 48 (41) 79 (27) 39 (43)
Period of study
Observational 130 (55) 52 (44) 0.06 1 158 (53) 44 (49) 0.49
Interventional 107 (45) 65 (56) 1.90 [1.14-3.18] 140 (47) 46 (51)
In bold, factors associated with renal dysfunction, in bold and italic: factors associated with RRT. MD, missing data; OR, odds ratio; RRT, renal replacement
therapy; SAPS II, simplified acute physiology score II; SOFA, sequential organ dysfunction score.
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Discussion
The present study focuses on the factors associated with
the occurrence of renal dysfunction in patients with
severe sepsis and septic shock. In our cohort, 73% of
patients were given a combination of HES and crystal-
loids. With respect to renal dysfunction [27], male gen-
der, a high SAPS II score, no decrease in SOFA scores,
the case-mix (surgery), and the interventional period of
the Sepsi d’Oc study were identified as risk factors for
renal dysfunction. The factors associated with the need
for RRT were the baseline value of plasma creatinine
and the need for vasopressors. The administration of
HES 130/0.4 in the first 24 hours of resuscitation was
not associated with a risk of renal dysfunction.
The Sepsi d’Oc study [23] was aimed at improving the
initial management (during the first 24 hours) of
patients with recent severe sepsis and/or septic shock (<
24 hours). Based on the Surviving Sepsis Campaign [3],
ten recommendations were implemented in 15 ICUs of
the Southern French ‘Languedoc Roussillon’ region. This
before-after study resulted in a 28 day-mortality reduc-
tion. This finding was concordant with those of recent,
large studies [28-32].
In the first 24 hours of management, more than 80%
of the patients received HES. The volume of colloids
was 830 ± 731 ml with a third quartile at 1,800 ml. The
use of comparable volumes of HES in patients with
severe sepsis or septic shock has already been reported
elsewhere [19,33]. In the present study, the volume of
infused HES was in the range of recommended doses, as
only 2% of patients received more than 50 ml/Kg of
HES. Our findings are globally consistent with the avail-
able literature, suggesting that our population is well-
representative of severe sepsis and septic shock patients.
Of note, the total volume during the initial period of
severe sepsis and or septic shock was lower than that
reported by other groups [29,34]. The occurrence of
renal dysfunction and the need for RRT are associated
with poorer outcomes, as previously reported [1,2,35].
In the Sepsi d’Oc study, the interventional period was
associated with a larger occurrence of renal dysfunction
but a higher 28-day survival rate. This finding suggests
that an optimization of the initial management of
patients with severe sepsis and septic shock may
decrease the impact of renal dysfunction on the out-
comes, as recently suggested by Badin et al.[36]. More-
over, the decrease in the 28-day mortality rate could
expose more patients to the risk of renal dysfunction.
The present study failed to show that a low molecular
weight HES is associated with poor renal outcomes. Initi-
ally, the potential deleterious effect of HES was demon-
strated in the renal graft setting with previous non-low
molecular weight types of HES [37,38]. The suggested
mechanism was an osmotic nephrosis. In ICU patients
with septic shock, Schortgen et al.[39] also reported that
more renal dysfunction was predominant in patients
receiving HES, but this did not result in an increase in
mortality or the need for RRT. In the VISEP study [15], a
higher rate of renal dysfunction was reported but this did
not impact the 90-day mortality rate. These previous stu-
dies used high molecular weight HES that were some-
times given in extremely large doses.
Some studies have shown that HES 130/0.4 is not asso-
ciated with the development of impaired renal function
[18,19]. In the renal graft setting, two studies have shown
that HES 130/0.4 is less deleterious in terms of renal
function than the old generations of HES and gelatins
[20,21]. Elsewhere, in ICU patients, three studies
reported that HES 130/0.4 administration was associated
with poor renal outcome [8,22,40]. In the study reported
by Bayer et al.[22], the baseline Central Venous Pressure
(CVP) value was lower and more albumin and platelets
and fresh frozen plasma were administrated in the HES
group than in the gelatin and crystalloids groups. More-
over, patients in the HES group were more exposed to
nephrotoxic product. These differences could explain
why more renal dysfunctions were observed in this group
without an increase in the need for RRT. In the study
reported by Shortgen et al.[40], patients requiring HES
administration previously received larger amounts of
fluids. Moreover, they required more mechanical ventila-
tion suggesting that they were more seriously ill whereas
the SAPS II score was similar. In contrast, other groups
reported similar findings to those of the present study
[18,19]. In the SOAP study [41], the infusion of HES was
more frequent in the most seriously ill patients (higher
baseline SAPS II and SOFA scores, more mechanically
ventilated patients, more patients requiring blood pro-
ducts, more patients with severe sepsis and more patients
with shock during their ICU stay) [18]. However, the
multivariate analysis did not find that HES were asso-
ciated with an increased risk of renal dysfunction. The
study reported by Boussekey et al.[19] also failed to find
a deleterious effect of HES in patients with severe sepsis
and/or septic shock. Moreover, volumes of infused HES
were similar to those reported in the present study (763
± 595 ml on day 2, 1,031 ± 800 ml on day 7, 1,361 ±
1,393 ml on day 21). Our study suggests that in a real life
situation, the physicians tend to respect the recom-
mended doses of HES. This could probably partly explain
the different results with previous studies in which HES
was widely given. The present study clearly shows that
the use of adequate dosages of HES is not associated with
the occurrence of renal dysfunction.
The present study has several limitations. First, it
focused on the use of different therapies in the first 24
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hours of initial management of patients with severe sep-
sis and/or septic shock. We cannot report the real
volume of fluid after 24 hours. However, Boussekey et
al.[19] showed that the main dosage of HES is admini-
strated in the first two days. Second, the present study
was a cohort study and several biases could interfere
with the findings. The physicians were not blinded, and
a pre-selection of patients may have played a role in our
results. However, this is a study reporting real-life prac-
tice, giving a partial response to an unresolved issue.
One should note that more than 70% of our patients
received both colloids and crystalloids, while rando-
mized clinical trials often favor the use of a single type
of fluid [15,39]. Even if a multivariate analysis was per-
formed, further randomized clinical trials will probably
provide a definitive answer.
Conclusions
In the present study, renal dysfunction was indepen-
dently associated with male gender, SAPS II score, a
surgical patient, no decrease in SOFA score in the first
24 hours, and the interventional period of the Sepsi
d’Oc study whereas RRT was independently associated
with the need for vasopressors and the baseline value of
serum creatinine. HES was widely used in patients with
severe sepsis and septic shock in the initial 24-hour per-
iod but was not associated with deleterious impacts on
renal function.
Key messages
• During the first 24 hours of severe sepsis or septic
shock, 379 (98%) of 388 patients received fluid
administration consisting exclusively of HES 130/0.4
(n = 39 (10%)) or crystalloids (n = 63 (17%)), or
both HES 130/0.4 and crystalloids (n = 276 (73%)).
The mean total amount of fluid given during the
first 24 hours was 3,780 ± 2,487 ml. The overall
mortality rate was 32%.
• RRT was required in 90 (23%) of 388 patients. The
need for vasopressors and the baseline value of
plasma creatinine were independently associated
with the need for RRT. The mortality rates were
52% in patients requiring RRT and 26% in those not
requiring RRT (P < 0.01).
• A renal dysfunction was diagnosed in 117 of 364
patients (32%) (34 patients were excluded because of
missing information concerning the initial course of
plasma creatinine). After multivariate analysis, male
gender, an increase in SAPS II scores, surgical
patients, no decrease in SOFA scores during the first
24 hours and the interventional period of the Sepsi
d’Oc study were independently associated with renal
dysfunction. The mortality rate was higher in
patients with renal dysfunction than in those without
renal dysfunction (48% versus 24%, P < 0.01).
• The use of HES was not associated with RRT or
renal dysfunction.
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